PMID- 30014595
OWN - NLM
STAT- MEDLINE
DCOM- 20190520
LR  - 20190520
IS  - 1545-5017 (Electronic)
IS  - 1545-5009 (Linking)
VI  - 65
IP  - 11
DP  - 2018 Nov
TI  - Carboplatin and vincristine neurotoxicity in the treatment of pediatric low-grade 
      gliomas.
PG  - e27351
LID - 10.1002/pbc.27351 [doi]
AB  - BACKGROUND: Pediatric low-grade gliomas (LGG) represent 30-50% of central nervous 
      system pediatric tumors. Over the last decades, the combination of carboplatin 
      and vincristine (CV) has become the first line of treatment in most centers. In a 
      large clinical trial where the efficacy of CV was compared to another regimen, 
      19% presented grade III neurotoxicity. Despite the fact that CV therapy is widely 
      used for pediatric patients with LGG, no study has reported detailed neurological 
      adverse events and outcome with this treatment regimen. The purpose of this 
      retrospective study is to better understand neurotoxicity associated with CV. 
      PROCEDURE: We conducted a retrospective study to better evaluate the incidence 
      and evolution of neurotoxicity associated with CV in patients with LGG. RESULTS: 
      Twenty-one pediatric patients were treated with CV at our single institution over 
      16 years. Most patients had optic glioma. Peripheral neuropathy was present in 
      most patients (86%). Eight patients (38%) had a dose reduction of vincristine due 
      to grade III toxicity (three motor neuropathies, three sensory neuropathies, one 
      constipation, and one dysphagia). Most neurotoxicity occurred during induction or 
      the first maintenance cycle. No ototoxicity was observed during treatment or 
      follow-up. CONCLUSIONS: In our study, neurotoxicity with vincristine occurred two 
      times more frequently than in previously published literature. Careful 
      neurological assessment is important to detect neurotoxicity, especially during 
      induction. The high incidence of neurotoxicity should be considered when 
      selecting a chemotherapy regimen for pediatric LGG.
CI  - (c) 2018 Wiley Periodicals, Inc.
FAU - Rosca, Lorena
AU  - Rosca L
AD  - Department of Pediatrics, Division of Child Neurology, CHU Sainte-Justine, 
      Montreal, Canada.
FAU - Robert-Boire, Viviane
AU  - Robert-Boire V
AD  - Department of Pediatrics, Division of Child Neurology, CHU Sainte-Justine, 
      Montreal, Canada.
FAU - Delisle, Jean-Francois
AU  - Delisle JF
AD  - Department of Pharmacy, CHU Sainte-Justine, Montreal, Canada.
FAU - Samson, Yvan
AU  - Samson Y
AD  - Department of Pediatrics, Division of Hemato-Oncology, CHU Sainte-Justine, 
      Montreal, Canada.
FAU - Perreault, Sebastien
AU  - Perreault S
AUID- ORCID: 0000-0002-4417-7698
AD  - Department of Pediatrics, Division of Child Neurology, CHU Sainte-Justine, 
      Montreal, Canada.
LA  - eng
PT  - Journal Article
DEP - 20180716
PL  - United States
TA  - Pediatr Blood Cancer
JT  - Pediatric blood & cancer
JID - 101186624
RN  - 5J49Q6B70F (Vincristine)
RN  - BG3F62OND5 (Carboplatin)
SB  - IM
MH  - Adolescent
MH  - Antineoplastic Combined Chemotherapy Protocols/*adverse effects
MH  - Brain Neoplasms/*drug therapy/mortality
MH  - Carboplatin/administration & dosage/adverse effects
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Glioma/*drug therapy/mortality
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Neurotoxicity Syndromes/*epidemiology/*etiology
MH  - Retrospective Studies
MH  - Vincristine/administration & dosage/adverse effects
OTO - NOTNLM
OT  - carboplatin
OT  - low-grade glioma
OT  - neuropathy
OT  - neurotoxicity
OT  - optic pathway glioma
OT  - vincristine
EDAT- 2018/07/18 06:00
MHDA- 2019/05/21 06:00
CRDT- 2018/07/18 06:00
PHST- 2018/01/03 00:00 [received]
PHST- 2018/06/01 00:00 [revised]
PHST- 2018/06/01 00:00 [accepted]
PHST- 2018/07/18 06:00 [pubmed]
PHST- 2019/05/21 06:00 [medline]
PHST- 2018/07/18 06:00 [entrez]
AID - 10.1002/pbc.27351 [doi]
PST - ppublish
SO  - Pediatr Blood Cancer. 2018 Nov;65(11):e27351. doi: 10.1002/pbc.27351. Epub 2018 
      Jul 16.